Abeona therapeutics announces positive pre-bla meeting with fda for eb-101 and plans for bla submission

Cleveland, aug. 30, 2023 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo) today announced the company's intention to proceed with the submission of a biologics license application (bla) to the u.s. food and drug administration (fda) for eb-101, its investigational autologous, engineered cell therapy, for patients with recessive dystrophic epidermolysis bullosa (rdeb) after the recent completion of a pre-bla meeting with the fda.
ABEO Ratings Summary
ABEO Quant Ranking